Exemestane vs Letrozole
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Aromatase · full HR+/HER2- Metastatic Breast Cancer pipeline
Exemestane
Marketed by Pfizer
NCT00002777 · Phase 3 · completed
The study used randomization and an active tamoxifen comparator with an estimated sample size of 342 participants. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT07163481 (registry estimate)
Reported efficacy
Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). (missed)
Result source: NCT00002777
Letrozole
Marketed by Novartis
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06974929 (registry estimate)
Reported efficacy
Disease-free survival (5 years): Estimated 4-year disease-free survival: letrozole 93% vs placebo 87% (75 vs 132 recurrences/new cancers out of 5187 enrolled); P<=0.001 (met)
Result source: NCT00003140
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
PFS, median
- Exemestane
- 7.3 vs 10vs CapecitabineNCT02028507
14 other results
- 3.5 NCT00253422
- 8 vs 10.6 NCT02028507
- 9.4 NCT03176238
- 8.5 NCT03176238
- 4.2 vs 3.7 NCT00767520
- 3.6 vs 3.7 NCT01381874
- 4.5 vs 3.7 NCT01381874
- 4.3 NCT00810797
- 7.9 vs 6.7 NCT02258451
- 4.1 NCT02049957
- 3.3 NCT02049957
- 5.5 NCT01743560
- 5.2 NCT02648477
- 1.8 NCT02648477
- Letrozole
- 20.2 vs 15.6vs Endocrine TherapyNCT00601900
17 other results
- 21.8 NCT03096847
- 8.8 NCT03096847
- 16.5 NCT03096847
- 21.8 vs 12.8 NCT03839823
- 20.1 vs 9.9 NCT00696072
- 25.1 NCT03822468
- 26.9 NCT03822468
- 29.4 NCT03633331
- 8 NCT03056755
- 5.6 NCT03056755
- 5.6 NCT03056755
- 9 NCT01231659
- 2.0 NCT00708214
- 3.5 NCT00708214
- 2.6 NCT00708214
- 5.2 NCT02648477
- 1.8 NCT02648477
OS, median
- Exemestane
- 33.7 vs 32vs CapecitabineNCT02028507
7 other results
- 22.5 NCT00253422
- 26.4 NCT01381874
- 25 vs 26.4 NCT02258451
- 15.9 NCT02049957
- 14 NCT02049957
- 15.6 NCT02648477
- 17.2 NCT02648477
- Letrozole
- 47.2 vs 43.9vs Endocrine TherapyNCT00601900
7 other results
- 35.6 NCT03633331
- 27.3 NCT03056755
- 29 NCT03056755
- 20.7 NCT03056755
- 22.3 NCT01231659
- 15.6 NCT02648477
- 17.2 NCT02648477
ORR
- Exemestane
- 14.3%bNCT01743560
6 other results
- 6.1% vs 0% NCT00767520
- 5.8% vs 6.3% NCT01381874
- 12.1% vs 6.3% NCT01381874
- 7% NCT02049957
- 0% NCT02049957
- 8.3% NCT00810797
- Letrozole
- 29.3%bNCT02941926
8 other results
- 45.3% NCT03822468
- 41.5% NCT03822468
- 37.2% NCT01231659
- 66.1% vs 61.8% NCT03839823
- 47.6% NCT01684215
- 19.3% NCT03056755
- 17.5% NCT03056755
- 25.2% NCT03056755
Clinical benefit rate
- Exemestane
- 48.2%bNCT03176238
10 other results
- 30.6% NCT03176238
- 44% NCT02049957
- 23% NCT02049957
- 30.6% vs 12.2% NCT00767520
- 9.6% vs 12.7% NCT01381874
- 22.7% vs 12.7% NCT01381874
- 28% NCT02049957
- 23% NCT02049957
- 50% NCT02648477
- 20% NCT02648477
- Letrozole
- 70.7%bNCT02941926
6 other results
- 81.3% vs 74.5% NCT03839823
- 46.2% NCT03056755
- 35.1% NCT03056755
- 38.3% NCT03056755
- 50% NCT02648477
- 20% NCT02648477
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety
Coverage. Exemestane: 15 of 15 rows · Letrozole: 15 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Exemestane Rows use multiple source trials | Letrozole Rows use multiple source trials |
|---|---|---|
| Clinical Benefit event count · % of participants No placebo or comparator arm | 23.8% (n=239)*a,b,c,d NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 57 Participants as posted | 70.7% (n=188)*600 mge,a,b,c,d NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 133 Participants as posted show 1 more dose75.5% (n=188)*400 mg NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 142 Participants as posted |
| Clinical Benefit responder rate · % of participants No placebo or comparator arm | 48.2% (n=199)e,f,d NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose30.6% (n=36) NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 70.7% (n=3246)f,d NCT02941926 · Phase 3 · registry result, not featured evidence · combination 5 other source trials46.2% (n=119) NCT03056755 · Phase 2 · registry result, not featured evidence · combination 35.1% (n=114) NCT03056755 · Phase 2 · registry result, not featured evidence · combination 38.3% (n=115) NCT03056755 · Phase 2 · registry result, not featured evidence · combination 50% (n=10) NCT02648477 · Phase 2 · registry result, not featured evidence · combination 20% (n=20) NCT02648477 · Phase 2 · registry result, not featured evidence · combination |
| Duration of Response time to event · months No placebo or comparator arm | 12.8 monthsa,b,c,d NCT00253422 · Phase 3 · registry result, not featured evidence | 13.8 monthse,a,b,c,d NCT03056755 · Phase 2 · registry result, not featured evidence · combination show 2 more doses6.5 months NCT03056755 · Phase 2 · registry result, not featured evidence · combination 16.5 months NCT03056755 · Phase 2 · registry result, not featured evidence · combination |
| ORR responder rate · % of participants No placebo or comparator arm | 14.3% (n=49) @ 48wkg,b,d NCT01743560 · Phase 4 · registry result, not featured evidence · combination 3 other source trials8.3% (n=36) NCT00810797 · Phase 2 · registry result, not featured evidence 0% (n=35)4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 7% (n=43)4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination | 29.3% (n=3246)g,b,d NCT02941926 · Phase 3 · registry result, not featured evidence · combination 7 other source trials19.3% (n=119) NCT03056755 · Phase 2 · registry result, not featured evidence · combination 17.5% (n=114) NCT03056755 · Phase 2 · registry result, not featured evidence · combination 25.2% (n=115) NCT03056755 · Phase 2 · registry result, not featured evidence · combination 41.5% (n=188)400 mg NCT03822468 · Phase 2 · registry result, not featured evidence 45.3% (n=188)600 mg NCT03822468 · Phase 2 · registry result, not featured evidence 47.6% (n=42)125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 37.2% (n=43) NCT01231659 · Phase 2 · registry result, not featured evidence · combination |
| ORR event count · % of participants No placebo or comparator arm | 4.2% (n=239)*a,b,c,d NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 10 Participants as posted 2 other source trials50% (n=10)* NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted 10% (n=20)* NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted | 50% (n=10)*e,a,b,c,d NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted show 1 more dose10% (n=20)* NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted |
| Overall Survival responder rate · % of participants No placebo or comparator arm | 74.2% (n=49) @ 48wkg,b NCT01743560 · Phase 4 · registry result, not featured evidence · combination | 93.3% (n=307) @ 48wke,g,b NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more doses87.5% (n=26) @ 48wk NCT03096847 · Phase 3 · registry result, not featured evidence · combination 86.1% (n=154) @ 48wk NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| Overall Survival time to event · months No placebo or comparator arm | 22.5 monthsb,c,d NCT00253422 · Phase 3 · registry result, not featured evidence 4 other source trials15.6 months NCT02648477 · Phase 2 · registry result, not featured evidence · combination 17.2 months NCT02648477 · Phase 2 · registry result, not featured evidence · combination 14 months4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 15.9 months4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination | NA monthse,b,c,d NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more dosesNA months NCT03096847 · Phase 3 · registry result, not featured evidence · combination NA months NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 5.45 months @ 48wk*g,b,d NCT01743560 · Phase 4 · registry result, not featured evidence · combination · converted to months from 23.6 weeks as posted 8 other source trials3.5 months NCT00253422 · Phase 3 · registry result, not featured evidence 9.37 months* NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 · converted to months from 40.6 weeks as posted 8.54 months* NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 · converted to months from 37 weeks as posted 5.2 months NCT02648477 · Phase 2 · registry result, not featured evidence · combination 1.8 months NCT02648477 · Phase 2 · registry result, not featured evidence · combination 4.3 months NCT00810797 · Phase 2 · registry result, not featured evidence 3.3 months4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 4.1 months4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination | 21.8 monthse,g,b,d NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more doses16.5 months NCT03096847 · Phase 3 · registry result, not featured evidence · combination 8.8 months NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| PFS responder rate · % of participants No placebo or comparator arm | 18.4% (n=49) @ 48wkg,b NCT01743560 · Phase 4 · registry result, not featured evidence · combination | 61.9% (n=307) @ 48wke,g,b NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more doses58.7% (n=26) @ 48wk NCT03096847 · Phase 3 · registry result, not featured evidence · combination 47.5% (n=154) @ 48wk NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| Time to Progression time to event · months No placebo or comparator arm | 6.9 monthsh,b,d NCT00201864 · Phase 2 · registry result, not featured evidence · combination | 27.1 monthsh,b,d NCT02941926 · Phase 3 · registry result, not featured evidence · combination |
| Time to Treatment Failure time to event · months No placebo or comparator arm | 3.4 monthsa,b,c,d NCT00253422 · Phase 3 · registry result, not featured evidence 2 other source trials1.85 months* NCT01870505 · Phase 1 · registry result, not featured evidence · combination · converted to months from 8 weeks as posted 3.92 months* NCT01870505 · Phase 1 · registry result, not featured evidence · combination · converted to months from 17 weeks as posted | 14.78 months*a,b,c,d NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 450 days as posted |
| Dropout rate | 29.6%i NCT01176916 · Phase 4 · registry result, not featured evidence show 40 more results—Everolimus + Exemestane NCT01743560 · Phase 4 · registry result, not featured evidence · combination 82.7%Everolimus and Exemestane NCT01743560 · Phase 4 · registry result, not featured evidence · combination 0.4% NCT00253422 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT02028507 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneAsian Everolimus + Exemestane NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 n/a: no completion milestoneNon-Asian Everolimus + Exemestane NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 0% NCT00083174 · Phase 3 · registry result, not featured evidence 0.1% NCT00036270 · Phase 3 · registry result, not featured evidence 0%Cohort 1 (Pembrolizumab, Doxorubic NCT02648477 · Phase 2 · registry result, not featured evidence · combination 0%Cohort 2 (Pembrolizumab, Anti-estr NCT02648477 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT02258451 · Phase 2 · registry result, not featured evidence · combination 0% NCT00810797 · Phase 2 · registry result, not featured evidence 71.7%Abiraterone Acetate + Exemestane + NCT01381874 · Phase 2 · registry result, not featured evidence · combination 70.8%Abiraterone Acetate + Prednisone NCT01381874 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone5 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone3 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 0% NCT00201864 · Phase 2 · registry result, not featured evidence · combination 13.9% NCT00767520 · Phase 2 · registry result, not featured evidence · combination 8.7% NCT00073073 · Phase 2 · registry result, not featured evidence — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination —125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 91.7%80mg bd 1w/1w + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination —80mg bd 2w/1w + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 100%80mg bd Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 100%40mg Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination —40mg bd Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 100%Part B: AZD4547 + Fulvestrant NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm B, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination | 0%Fixed Dose Letrozolej NCT01035099 · Phase 4 · registry result, not featured evidence show 47 more results0%Titrated Dose Letrozole NCT01035099 · Phase 4 · registry result, not featured evidence 69.1%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 34%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination 0% NCT00601900 · Phase 3 · registry result, not featured evidence · combination 59.9% NCT02941926 · Phase 3 · registry result, not featured evidence · combination 68.7%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination —Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 76.9%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 87.9%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02600923 · Phase 3 · registry result, not featured evidence · combination 0% NCT00754845 · Phase 3 · registry result, not featured evidence 1.1% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 99.2%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 100%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 92.1%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence n/a: no completion milestone400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence 0%Cohort 1 (Pembrolizumab, Doxorubic NCT02648477 · Phase 2 · registry result, not featured evidence · combination 0%Cohort 2 (Pembrolizumab, Anti-estr NCT02648477 · Phase 2 · registry result, not featured evidence · combination 68.8%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 1.4% NCT03644186 · Phase 2 · registry result, not featured evidence · combination 1.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 0% NCT00530868 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —2.5 mg daily NCT00579826 · Phase 2 · registry result, not featured evidence 17.2%Letrozole NCT00579826 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT01231659 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT00696072 · Phase 2 · registry result, not featured evidence · combination 12.1% NCT00090857 · Phase 2 · registry result, not featured evidence 12.5% NCT00867217 · Phase 2 · registry result, not featured evidence 12.5% NCT01129622 · Phase 2 · registry result, not featured evidence n/a: no completion milestone50 mg with letrozole NCT00708214 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone40 mg with letrozole NCT00708214 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone30 mg with letrozole NCT00708214 · Phase 2 · registry result, not featured evidence · combination 100%75 mg intermittent NCT00062751 · Phase 2 · registry result, not featured evidence · combination 100%30 mg intermittent NCT00062751 · Phase 2 · registry result, not featured evidence · combination 83.3%25 mg daily NCT00062751 · Phase 2 · registry result, not featured evidence · combination 100%10 mg daily NCT00062751 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 10.8%i NCT01176916 · Phase 4 · registry result, not featured evidence show 40 more results—Everolimus + Exemestane NCT01743560 · Phase 4 · registry result, not featured evidence · combination 15.4%Everolimus and Exemestane NCT01743560 · Phase 4 · registry result, not featured evidence · combination — NCT00253422 · Phase 3 · registry result, not featured evidence 5.2% NCT02028507 · Phase 3 · registry result, not featured evidence · combination —Asian Everolimus + Exemestane NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Non-Asian Everolimus + Exemestane NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 — NCT00083174 · Phase 3 · registry result, not featured evidence — NCT00036270 · Phase 3 · registry result, not featured evidence —Cohort 1 (Pembrolizumab, Doxorubic NCT02648477 · Phase 2 · registry result, not featured evidence · combination —Cohort 2 (Pembrolizumab, Anti-estr NCT02648477 · Phase 2 · registry result, not featured evidence · combination 11.3% NCT02258451 · Phase 2 · registry result, not featured evidence · combination — NCT00810797 · Phase 2 · registry result, not featured evidence —Abiraterone Acetate + Exemestane + NCT01381874 · Phase 2 · registry result, not featured evidence · combination —Abiraterone Acetate + Prednisone NCT01381874 · Phase 2 · registry result, not featured evidence · combination 16.7%5 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 0%4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 17.1%4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 11.6%4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 33.3%3 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination — NCT00201864 · Phase 2 · registry result, not featured evidence · combination — NCT00767520 · Phase 2 · registry result, not featured evidence · combination — NCT00073073 · Phase 2 · registry result, not featured evidence — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination —125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 33.3%80mg bd 1w/1w + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination —80mg bd 2w/1w + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 40%80mg bd Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 20%40mg Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination —40mg bd Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 0%Part B: AZD4547 + Fulvestrant NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination —DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —DOSE FINDING PHASE, Arm B, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination | —Fixed Dose Letrozolej NCT01035099 · Phase 4 · registry result, not featured evidence show 47 more results—Titrated Dose Letrozole NCT01035099 · Phase 4 · registry result, not featured evidence 3.9%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 2%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination — NCT00601900 · Phase 3 · registry result, not featured evidence · combination 15.5% NCT02941926 · Phase 3 · registry result, not featured evidence · combination 22.6%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination —Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 23.1%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 17.8%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02600923 · Phase 3 · registry result, not featured evidence · combination — NCT00754845 · Phase 3 · registry result, not featured evidence — NCT03633331 · Phase 2 · registry result, not featured evidence · combination 15.7%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 11.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 10.3%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 12.8%600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence 11.2%400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence —Cohort 1 (Pembrolizumab, Doxorubic NCT02648477 · Phase 2 · registry result, not featured evidence · combination —Cohort 2 (Pembrolizumab, Anti-estr NCT02648477 · Phase 2 · registry result, not featured evidence · combination 7.1%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence — NCT03644186 · Phase 2 · registry result, not featured evidence · combination — NCT03007979 · Phase 2 · registry result, not featured evidence · combination — NCT00530868 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —2.5 mg daily NCT00579826 · Phase 2 · registry result, not featured evidence —Letrozole NCT00579826 · Phase 2 · registry result, not featured evidence 12.5% NCT01231659 · Phase 2 · registry result, not featured evidence · combination 17.5% NCT00696072 · Phase 2 · registry result, not featured evidence · combination 6.1% NCT00090857 · Phase 2 · registry result, not featured evidence — NCT00867217 · Phase 2 · registry result, not featured evidence — NCT01129622 · Phase 2 · registry result, not featured evidence 42.9%50 mg with letrozole NCT00708214 · Phase 2 · registry result, not featured evidence · combination 46.2%40 mg with letrozole NCT00708214 · Phase 2 · registry result, not featured evidence · combination 25%30 mg with letrozole NCT00708214 · Phase 2 · registry result, not featured evidence · combination 33.3%75 mg intermittent NCT00062751 · Phase 2 · registry result, not featured evidence · combination 23.3%30 mg intermittent NCT00062751 · Phase 2 · registry result, not featured evidence · combination 33.3%25 mg daily NCT00062751 · Phase 2 · registry result, not featured evidence · combination 12.1%10 mg daily NCT00062751 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 6.8%i NCT01176916 · Phase 4 · registry result, not featured evidence show 40 more results44.9%Everolimus + Exemestane NCT01743560 · Phase 4 · registry result, not featured evidence · combination —Everolimus and Exemestane NCT01743560 · Phase 4 · registry result, not featured evidence · combination 15.6% NCT00253422 · Phase 3 · registry result, not featured evidence 22.7% NCT02028507 · Phase 3 · registry result, not featured evidence · combination —Asian Everolimus + Exemestane NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Non-Asian Everolimus + Exemestane NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 1.7% NCT00083174 · Phase 3 · registry result, not featured evidence 17.1% NCT00036270 · Phase 3 · registry result, not featured evidence 30%Cohort 1 (Pembrolizumab, Doxorubic NCT02648477 · Phase 2 · registry result, not featured evidence · combination 10%Cohort 2 (Pembrolizumab, Anti-estr NCT02648477 · Phase 2 · registry result, not featured evidence · combination 43.9% NCT02258451 · Phase 2 · registry result, not featured evidence · combination 11.1% NCT00810797 · Phase 2 · registry result, not featured evidence 26.9%Abiraterone Acetate + Exemestane + NCT01381874 · Phase 2 · registry result, not featured evidence · combination 20.7%Abiraterone Acetate + Prednisone NCT01381874 · Phase 2 · registry result, not featured evidence · combination 16.7%5 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 33.3%4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 14.3%4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 25.6%4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 0%3 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination — NCT00201864 · Phase 2 · registry result, not featured evidence · combination 27.8% NCT00767520 · Phase 2 · registry result, not featured evidence · combination 0% NCT00073073 · Phase 2 · registry result, not featured evidence 25% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 100%125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 83.3%100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 87.5%100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 41.7%80mg bd 1w/1w + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 11.1%80mg bd 2w/1w + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 40%80mg bd Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination —40mg Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 40%40mg bd Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 20%Part B: AZD4547 + Fulvestrant NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 25%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 57.1%DOSE FINDING PHASE, Arm B, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 50%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 33.3%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 16.7%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 28.6%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination | 0%Fixed Dose Letrozolej NCT01035099 · Phase 4 · registry result, not featured evidence show 47 more results0%Titrated Dose Letrozole NCT01035099 · Phase 4 · registry result, not featured evidence 29.6%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 18%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination 28.7% NCT00601900 · Phase 3 · registry result, not featured evidence · combination — NCT02941926 · Phase 3 · registry result, not featured evidence · combination 30.4%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination 27.3%Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 19.2%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 28.7%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 24.6% NCT02600923 · Phase 3 · registry result, not featured evidence · combination — NCT00754845 · Phase 3 · registry result, not featured evidence 38% NCT03633331 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 29.1%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 0%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 38.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30.2%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —600 mg NCT03822468 · Phase 2 · registry result, not featured evidence 19.7%600mg NCT03822468 · Phase 2 · registry result, not featured evidence —400 mg NCT03822468 · Phase 2 · registry result, not featured evidence 20.2%400mg NCT03822468 · Phase 2 · registry result, not featured evidence 30%Cohort 1 (Pembrolizumab, Doxorubic NCT02648477 · Phase 2 · registry result, not featured evidence · combination 10%Cohort 2 (Pembrolizumab, Anti-estr NCT02648477 · Phase 2 · registry result, not featured evidence · combination —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 15.2%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 54.2% NCT03644186 · Phase 2 · registry result, not featured evidence · combination 27.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 4% NCT00530868 · Phase 2 · registry result, not featured evidence · combination 9.5%125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 33.3%125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 0%2.5 mg daily NCT00579826 · Phase 2 · registry result, not featured evidence —Letrozole NCT00579826 · Phase 2 · registry result, not featured evidence 36.1% NCT01231659 · Phase 2 · registry result, not featured evidence · combination 24.6% NCT00696072 · Phase 2 · registry result, not featured evidence · combination 3% NCT00090857 · Phase 2 · registry result, not featured evidence 3.8% NCT00867217 · Phase 2 · registry result, not featured evidence 0% NCT01129622 · Phase 2 · registry result, not featured evidence 14.3%50 mg with letrozole NCT00708214 · Phase 2 · registry result, not featured evidence · combination 23.1%40 mg with letrozole NCT00708214 · Phase 2 · registry result, not featured evidence · combination 62.5%30 mg with letrozole NCT00708214 · Phase 2 · registry result, not featured evidence · combination 16.7%75 mg intermittent NCT00062751 · Phase 2 · registry result, not featured evidence · combination 33.3%30 mg intermittent NCT00062751 · Phase 2 · registry result, not featured evidence · combination 33.3%25 mg daily NCT00062751 · Phase 2 · registry result, not featured evidence · combination 36.4%10 mg daily NCT00062751 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | i arthralgia 9% vaginal haemorrhage 5.9% NCT01176916 · Phase 4 · registry result, not featured evidence show 35 more resultsdiarrhoea 44.9% fatigue 44.9% cough 36.7% NCT01743560 · Phase 4 · registry result, not featured evidence · combination lethargy 56.1% arthralgia 46.4% vomiting 38.4% NCT00253422 · Phase 3 · registry result, not featured evidence neutrophil count decreased 62.7% fatigue 55.3% hypertension 34% NCT02028507 · Phase 3 · registry result, not featured evidence · combination hot flashes 40.2% (placebo 31.9%) pain joint 29.7% (placebo 27%) fatigue 23.4% (placebo 20.7%) NCT00083174 · Phase 3 · registry result, not featured evidence hot flush 31.3% arthralgia 23.8% fatigue 16.4% NCT00036270 · Phase 3 · registry result, not featured evidence fatigue 90% nausea 90% white blood cell decreased 90% NCT02648477 · Phase 2 · registry result, not featured evidence · combination fatigue 75% alkaline phosphatase increased 50% aspartate aminotransferase increased 45% NCT02648477 · Phase 2 · registry result, not featured evidence · combination stomatitis 47.5% (placebo 49.6%) anaemia 39.6% (placebo 28.8%) decreased appetite 34.5% (placebo 25.2%) NCT02258451 · Phase 2 · registry result, not featured evidence · combination hot flashes 66.7% blood glucose increased 61.1% aspartate aminotransferase increased 58.3% NCT00810797 · Phase 2 · registry result, not featured evidence nausea 21.2% fatigue 20.2% vomiting 18.3% NCT01381874 · Phase 2 · registry result, not featured evidence · combination fatigue 27.6% nausea 24.1% hypokalaemia 21.8% NCT01381874 · Phase 2 · registry result, not featured evidence · combination 5 mg + Exemestane nausea 100% stomatitis 83.3% fatigue 66.7% NCT02049957 · Phase 2 · registry result, not featured evidence · combination 4 mg + Exemestane diarrhoea 66.7% fatigue 66.7% nausea 50% NCT02049957 · Phase 2 · registry result, not featured evidence · combination 4 mg + Exemestane fatigue 45.7% hyperglycaemia 45.7% nausea 42.9% NCT02049957 · Phase 2 · registry result, not featured evidence · combination 4 mg + Exemestane nausea 53.5% fatigue 44.2% diarrhoea 39.5% NCT02049957 · Phase 2 · registry result, not featured evidence · combination 3 mg + Exemestane dyspepsia 100% abdominal pain 66.7% arthralgia 66.7% NCT02049957 · Phase 2 · registry result, not featured evidence · combination nausea 36.7% (placebo 30.3%) diarrhoea 31.6% (placebo 9.2%) asthenia 26.6% (placebo 10.5%) NCT00767520 · Phase 2 · registry result, not featured evidence · combination hot flashes 33.3% arthralgia 31% fatigue 11.9% NCT00073073 · Phase 2 · registry result, not featured evidence cough 25% dizziness 25% dyspnoea 25% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 125mg mucositis oral 100% neutrophil count decreased 100% platelet count decreased 100% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 100mg mucositis oral 100% neutrophil count decreased 83.3% fatigue 50% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 100mg mucositis oral 96.9% neutrophil count decreased 87.5% fatigue 65.6% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 80mg bd 1w/1w + Ex 25mg dry mouth 58.3% (placebo 0%) alopecia 50% (placebo 0%) dysgeusia 50% (placebo 0%) NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 80mg bd 2w/1w + Ex 25mg dysgeusia 66.7% (placebo 0%) alopecia 55.6% (placebo 0%) dry mouth 55.6% (placebo 0%) NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 80mg bd Cont + Ex 25mg alopecia 100% (placebo 0%) dry mouth 80% (placebo 0%) diarrhoea 60% (placebo 0%) NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 40mg bd Cont + Ex 25mg constipation 80% (placebo 0%) alopecia 60% (placebo 0%) dry mouth 60% (placebo 0%) NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination dry mouth 80% (placebo 0%) alopecia 40% (placebo 0%) asthenia 40% (placebo 0%) NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination rash maculo-papular 33.3% abdominal pain 0% alanine aminotransferase increased 0% NCT01870505 · Phase 1 · registry result, not featured evidence · combination rash maculo-papular 50% abdominal pain 25% alkaline phosphatase increased 25% NCT01870505 · Phase 1 · registry result, not featured evidence · combination aspartate aminotransferase increased 28.6% abdominal pain 14.3% blood bilirubin increased 14.3% NCT01870505 · Phase 1 · registry result, not featured evidence · combination rash maculo-papular 33.3% confusion 16.7% lymphocyte count decreased 16.7% NCT01870505 · Phase 1 · registry result, not featured evidence · combination lymphocyte count decreased 33.3% rash maculo-papular 33.3% anemia 16.7% NCT01870505 · Phase 1 · registry result, not featured evidence · combination abdominal pain 0% alanine aminotransferase increased 0% alkaline phosphatase increased 0% NCT01870505 · Phase 1 · registry result, not featured evidence · combination aspartate aminotransferase increased 33.3% rash maculo-papular 33.3% alkaline phosphatase increased 16.7% NCT01870505 · Phase 1 · registry result, not featured evidence · combination lymphocyte count decreased 42.9% neutrophil count decreased 42.9% white blood cell decreased 42.9% NCT01870505 · Phase 1 · registry result, not featured evidence · combination | show 38 more resultsneutropenia 72.4% fatigue 65.1% nausea 37.5% NCT02679755 · Phase 4 · registry result, not featured evidence · combination neutropenia 57% anaemia 22% alopecia 17% NCT02679755 · Phase 4 · registry result, not featured evidence · combination arthralgia 70.3% hypertension 59% proteinuria 47.7% NCT00601900 · Phase 3 · registry result, not featured evidence · combination neutropenia 50.8% nausea 40.8% fatigue 38.6% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutropenia 48.1% nausea 42.1% fatigue 40.4% NCT03096847 · Phase 3 · registry result, not featured evidence · combination fatigue 57.7% neutropenia 57.7% hot flush 42.3% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutropenia 46.5% nausea 43.3% fatigue 37.6% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutropenia 70% leukopenia 34.6% anaemia 33.8% NCT02600923 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 92.4% white blood cell decreased 87% fatigue 84.8% NCT03633331 · Phase 2 · registry result, not featured evidence · combination diarrhoea 64.6% hyperglycaemia 59.8% nausea 46.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination asthenia 100% blood creatinine increased 100% diarrhoea 100% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 68.3% hyperglycaemia 64.3% nausea 54% NCT03056755 · Phase 2 · registry result, not featured evidence · combination hyperglycaemia 67.5% diarrhoea 54% nausea 40.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 70% hyperglycaemia 60% fatigue 50% NCT03056755 · Phase 2 · registry result, not featured evidence · combination 600mg neutropenia 66.5% leukopenia 27.7% anaemia 26.1% NCT03822468 · Phase 2 · registry result, not featured evidence 400mg neutropenia 53.2% alanine aminotransferase increased 26.1% aspartate aminotransferase increased 21.8% NCT03822468 · Phase 2 · registry result, not featured evidence fatigue 90% nausea 90% white blood cell decreased 90% NCT02648477 · Phase 2 · registry result, not featured evidence · combination fatigue 75% alkaline phosphatase increased 50% aspartate aminotransferase increased 45% NCT02648477 · Phase 2 · registry result, not featured evidence · combination 600 mg neutropenia 65.2% anaemia 35.7% leukopenia 25.9% NCT03839823 · Phase 2 · registry result, not featured evidence diarrhea 65.3% anemia 48.6% platelet count decreased 38.9% NCT03644186 · Phase 2 · registry result, not featured evidence · combination white blood cell count decreased 96.3% neutrophil count decreased 87% anemia 79.6% NCT03007979 · Phase 2 · registry result, not featured evidence · combination headache 4% NCT00530868 · Phase 2 · registry result, not featured evidence · combination 125 mg + 2.5 mg neutrophil count decreased 81% stomatitis 76.2% white blood cell count decreased 71.4% NCT01684215 · Phase 2 · registry result, not featured evidence · combination 125 mg + 2.5 mg neutrophil count decreased 100% white blood cell count decreased 100% diarrhoea 66.7% NCT01684215 · Phase 2 · registry result, not featured evidence · combination 2.5 mg daily musculoskeletal pain 17.2% (placebo 11.5%) atrial tachycardia 3.4% (placebo 0%) cataract 3.4% (placebo 0%) NCT00579826 · Phase 2 · registry result, not featured evidence fatigue 68.1% stomatitis 37.5% decreased appetite 33.3% NCT01231659 · Phase 2 · registry result, not featured evidence · combination fatigue 50.9% nausea 45.6% pain 33.3% NCT00696072 · Phase 2 · registry result, not featured evidence · combination pain - muscle 6.1% (placebo 6.3%) arthritis (non-septic) 3% (placebo 0%) dizziness 3% (placebo 0%) NCT00090857 · Phase 2 · registry result, not featured evidence joint function 12.5% (placebo 11.3%) arthralgia 8.8% (placebo 5%) fatigue 7.5% (placebo 11.3%) NCT00867217 · Phase 2 · registry result, not featured evidence 50 mg with letrozole diarrhoea 100% acne 71.4% mucosal inflammation 71.4% NCT00708214 · Phase 2 · registry result, not featured evidence · combination 40 mg with letrozole diarrhoea 92.3% asthenia 61.5% dermatitis acneiform 38.5% NCT00708214 · Phase 2 · registry result, not featured evidence · combination 30 mg with letrozole diarrhoea 87.5% rash 75% asthenia 50% NCT00708214 · Phase 2 · registry result, not featured evidence · combination 75 mg intermittent asthenia 100% mucositis 66.7% dry mouth 50% NCT00062751 · Phase 2 · registry result, not featured evidence · combination 30 mg intermittent asthenia 70% diarrhea 50% mucositis 50% NCT00062751 · Phase 2 · registry result, not featured evidence · combination 25 mg daily anemia 83.3% asthenia 83.3% arthralgia 66.7% NCT00062751 · Phase 2 · registry result, not featured evidence · combination 10 mg daily peripheral edema 48.5% asthenia 45.5% diarrhea 39.4% NCT00062751 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation context differs: eligible sex differs (ALL versus FEMALE).
- gTrial phases differ: Phase 3 versus Phase 4.
- hTrial phases differ: Phase 3 versus Phase 2.
- iPopulation comparability has not been reviewed for 39 of these studies.
- jPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Exemestane
show 2 more results
+ 42 further endpoints in the CSV export.
Letrozole
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
+ 67 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Exemestane's landscape · Letrozole's landscape